Advancedmolecular
Histone Modification
Overview
Histones carry >100 post-translational modifications (acetyl, methyl, phosphate, ubiquitin...) on their tails, forming a 'histone code' read by effector proteins. Acetylation (H3K27ac, H3K9ac) marks active chromatin by neutralizing lysine charge; methylation's meaning depends on residue (H3K4me3 = active promoters, H3K27me3 = Polycomb repression, H3K9me3 = heterochromatin). Writers, readers, and erasers make the code dynamic and druggable.
Learning objectives
- List major histone marks and their meanings
- Explain how acetylation opens chromatin
- Describe Polycomb vs Trithorax systems
- Explain therapeutic targeting of histone modifiers
Acetylation: the activation mark
HATs (p300/CBP) acetylate lysines, neutralizing their positive charge and loosening DNA-histone grip; bromodomain readers then recruit transcription machinery. HDACs reverse it. H3K27ac marks active enhancers; H3K9ac marks active promoters. HDAC inhibitors (vorinostat) are approved for cutaneous T-cell lymphoma.
Acetylation physically loosens chromatin: chemistry with immediate mechanical effect.
Methylation: context is everything
H3K4me3: active promoters (Trithorax/COMPASS). H3K27me3: Polycomb-repressed developmental genes. H3K9me3: constitutive heterochromatin (SUV39H/HP1). H3K36me3: transcribed gene bodies. Same methyl group, opposite meanings depending on residue: the code's subtlety.
Never say 'histone methylation activates/represses' without naming the lysine.
Polycomb vs Trithorax
These antagonistic systems maintain developmental gene states through division: Polycomb (PRC2/EZH2 deposits H3K27me3) keeps lineage genes silent; Trithorax (MLL/COMPASS deposits H3K4me3) keeps them ready. Bivalent domains (both marks) poise developmental genes in stem cells.
Stem-cell developmental genes carry both H3K4me3 and H3K27me3: poised, not committed.
Disease and drugs
EZH2 gain-of-function in lymphomas (tazemetostat approved); MLL translocations in leukemia; histone H3K27M mutations in pediatric gliomas (oncohistones) that poison PRC2 globally. The histone-modifier drug pipeline is one of oncology's busiest.
Single histone mutations (H3K27M) can dominantly reprogram the entire epigenome: a new cancer paradigm.
Key points
- Acetylation (H3K27ac/H3K9ac) opens chromatin for activity
- Methylation meaning is residue-specific: H3K4me3 active, H3K27me3 Polycomb-repressed, H3K9me3 heterochromatin
- Polycomb/Trithorax maintain developmental states; bivalent domains poise stem-cell genes
- EZH2, MLL, oncohistones are therapeutic targets
Common misconceptions
✓ Truth: H3K4me3 marks the most active promoters; only specific residues (H3K27, H3K9) are repressive.
✓ Truth: It is dynamic and combinatorial: marks are added/removed continuously and read in combination.
Practice questions
Q1. H3K27ac marks which chromatin feature?
- Repressed promoters
- Active enhancers
- Centromeres
- Telomeres
Acetylated H3K27 is the signature of active enhancers.
Q2. H3K27me3 is deposited by
- COMPASS
- Polycomb PRC2/EZH2
- p300
- DNMT1
PRC2's EZH2 methylates H3K27 for developmental gene repression.
Q3. HDAC inhibitors treat cancer by
- Removing acetylation
- Preventing deacetylation, reopening silenced genes
- Cutting DNA
- Blocking ribosomes
They preserve acetylation, reactivating silenced tumor suppressors.
Click a question to reveal the answer and explanation.
Frequently asked questions
What do bromodomain inhibitors do?
They block acetyl-lysine readers (e.g., BRD4), collapsing oncogenic transcription programs: tested in NUT carcinoma, AML.
How does H3K27M cause cancer?
The mutant histone binds and inhibits PRC2, globally depleting H3K27me3 and unleashing developmental genes.
What is ChIP-seq?
Chromatin immunoprecipitation + sequencing maps where histone marks (or TFs) sit genome-wide: how the code was cracked.